Plus Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 20
- Market Cap
- -
- Introduction
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
- Conditions
- EpendymomaHigh Grade Gliomas
- Interventions
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Plus Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT07061626
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Plus Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT05460507
- Locations
- 🇺🇸
The Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Plus Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05034497
- Locations
- 🇺🇸
Northwestern Memorial Hospital Olson Pavilion, Chicago, Illinois, United States
🇺🇸Northshore University Hospital, Manhasset, New York, United States
🇺🇸Lenox Hill Hospital, New York, New York, United States
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- Conditions
- Glioma
- Interventions
- Drug: Rhenium Liposome Treatment
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Plus Therapeutics
- Target Recruit Count
- 55
- Registration Number
- NCT01906385
- Locations
- 🇺🇸
Northshore University Hospital, Manhasset, New York, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸The Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States
News
Plus Therapeutics Prepares CNSide Diagnostics Platform for U.S. Commercial Launch in Second Half 2025
Plus Therapeutics announced plans to commercially launch its CNSide CSF Assay Platform in the second half of 2025, targeting an underserved CNS cancer diagnostic market estimated at over $6 billion in the U.S.
Plus Therapeutics Restructures $15 Million Equity Financing to Eliminate Potential 1.5 Billion Share Dilution
Plus Therapeutics announced a comprehensive restructuring of its March 2025 equity financing that eliminates the potential issuance of up to 1.5 billion shares of common stock.
Novel Radiotherapeutic Rhenium Obisbemeda Doubles Survival Time in Glioblastoma Patients
A Phase 1 trial led by UT Health San Antonio demonstrated that Rhenium Obisbemeda more than doubled median survival time to 17 months in recurrent glioblastoma patients receiving high doses, compared to the typical 8-month survival.
Phase 1 Trial Shows Rhenium (186Re) Obisbemeda Doubles Survival in Recurrent Glioblastoma Patients
Plus Therapeutics' Rhenium (186Re) Obisbemeda demonstrated a median overall survival of 17 months in patients receiving >100 Gy radiation dose, significantly outperforming the standard of care's 8-month survival rate.
Plus Therapeutics Receives FDA Orphan Drug Designation for Novel Lung Cancer Metastasis Treatment
Plus Therapeutics has secured FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda, targeting leptomeningeal metastases in lung cancer patients.
FDA Grants Orphan Drug Designation to Rhenium Obisbemeda for Lung Cancer Leptomeningeal Metastases
Plus Therapeutics receives FDA Orphan Drug Designation for Rhenium Obisbemeda, targeting the treatment of leptomeningeal metastases in lung cancer patients, offering potential market exclusivity and regulatory benefits.
Plus Therapeutics Raises $5.7M to Advance Novel Radiotherapy for Leptomeningeal Metastases
Plus Therapeutics secured $5.7 million in funding through a $3.7M private placement and $2.0M advance from CPRIT to support their Rhenium-186 radiotherapy development for leptomeningeal metastases.
CNSide CSF Assay Shows Promise in Leptomeningeal Metastases Diagnosis
• The FORESEE trial demonstrated that the CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases, exceeding the target endpoint. • CNSide exhibited enhanced sensitivity in detecting tumor cells (80%) compared to standard CSF cytology (29%) in patients with LM, improving diagnostic accuracy. • The assay identified actionable mutations, such as HER2 amplification, in CSF, impacting 24% of therapeutic selection decisions and demonstrating clinical utility. • High specificity and improved negative predictive value of CNSide aids in ruling out LM, offering a more reliable diagnostic tool for at-risk patients.
Plus Therapeutics Receives FDA Clearance for Phase 1 Trial of Rhenium-186 Obisbemeda in Recurrent Glioblastoma
Plus Therapeutics has been granted FDA approval to proceed with a Phase 1 clinical trial evaluating Rhenium-186 Obisbemeda for the treatment of recurrent glioblastoma.
Rhenium-186 Obisbemeda Shows Promise in Recurrent Glioblastoma Trial
Plus Therapeutics' ReSPECT-GBM Phase 1/2 trial update reveals Rhenium-186 Obisbemeda's favorable safety profile and potential efficacy in recurrent glioblastoma treatment.